Prof. Irene Lang discusses the biological mechanisms of chronic thromboembolic pulmonary hypertension (CTEPH), which may occur as a rare complication after acute pulmonary embolism. While the exact epidemiology is unknown, Prof. Lang discusses the latest knowledge on how CTEPH develops, the role of vascular disease, and how small-vessel disease may impact on the severity of CTEPH and post-surgical outcomes.1/3 Next Interview
Prof. Marc Humbert discusses the important advances in the management of patients with inoperable disease or persistent/recurrent pulmonary hypertension after pulmonary endarterectomy. This includes discussion of how and when to use medical therapies, the role of balloon angioplasty and when to consider anticoagulation therapy.2/3 Next Interview
Dr Mark Toshner discusses what we know about current and emerging medical therapies in the management of patients with CTEPH and how different treatments and procedures can be fully utilized to give patients the best outcomes.3/3 Take CME Test
Overview & Learning Objectives
In this activity, experts in cardiology, pulmonary vascular disorder and respiratory specialists discuss the biological and pathophysiological mechanisms of CTEPH and how they impact on treatment decisions relating to the use of medical therapies in daily clinical practice.
This activity has been jointly provided by Oakstone and touchIME. Oakstone Publishing is accredited by the ACCME to provide continuing medical education to physicians.
This activity is designed to meet the educational needs of pulmonologists, cardiologists, cardiopulmonary surgeons, rheumatologists and other HCPs involved in the care of patients with CTEPH globally.
Oakstone Publishing has assessed conflict of interest with its faculty, authors, editors, and any individuals who were in a position to control the content of this CME activity. Any identified relevant conflicts of interest were resolved for fair balance and scientific objectivity of studies utilized in this activity. Oakstone Publishing’s planners, content reviewers, and editorial staff disclose no relevant commercial interests.
Prof. Irene Lang discloses: Grants/research support: Actelion, AOPOrphan, Consultant/Advisory Boards: Actelion, AOPOrphan, Medtronic, Ferrer
Prof. Marc Humbert discloses: Grants/research support: Bayer, GSK, Actelion, Consultant/Advisory Boards: Actelion, Bayer, GSK, Merck, United Therapeutics, Acceleron
Dr Mark Toshner discloses: Consultant/Advisory Boards: Morphogen-IX
Walter Murray Yarbrough, MD has no financial interests/relationships or affiliations in relation to this activity.
Touch Medical Writer
Paul Taylor has no financial interests/relationships or affiliations in relation to this activity.
Requirement for Successful Completion
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Oakstone Publishing and touchIME. Oakstone Publishing is accredited by the ACCME to provide continuing medical education for physicians.
Oakstone Publishing designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™️. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In order to receive credit for this activity, participants must review and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain CME credit. Statements of credit are awarded upon successful completion of the post-test and evaluation form.
Date of original release: April 21, 2020. Date credits expire: April 21, 2021.
After watching this touchEXPERT OPINIONS, you should be able to:
- Describe the biological and pathophysiological mechanisms of CTEPH
- Summarize the evolving data supporting the use of oral therapies
- Explain how new developments in medical therapy for the treatment of CTEPH will change daily practice